Division of Compugen Ltd.
Latest From Compugen Inc.
Bristol-Myers Squibb is teaming up with Compugen to test the latter’s investigational antibody that targets a new checkpoint, PVRIG, in combination with its own antibody Opdivo. Combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT, is also on the cards for the future.
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.
With the Supreme Court upholding the Patient Protection and Affordable Care Act, the pharma sector can look forward to a projected 8.8% increase in prescription drug spending in 2014.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Compugen Ltd.
- Senior Management
Vincent R Zurawski, Jr., PhD, Pres. & CEO
Eli Mintz, Pres.
Simchon Faigler, EVP, CTO
Salomon Z Langer, MD, VP, Molecular Biology & Drug Discovery
- Contact Info
Phone: (609) 655-5105
7 Centre Dr., White Oak Bldg.
Jamesburg, NJ 08831
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.